This new patent strenghtens the protection and the potential of the « First in Class » drug candidate pf the Company. it allows to develop an oral formulation whch acts directly on the gut microbiota of T2DM patients [♦ October 2021].
Emmanuel Macron, French President, announced an ambitious plan prepared by the 5 Qualified Personalities including Lyse Santoro, CEO of THAC: 7 billion euros to boost healthcare Innovation, in particular in companies such as THAC [♦ June 2021].
[PRESS RELEASE] – Launch of the CSIS 2021
Lyse Santoro, CEO of THAC, is nominated by the French Government as Qualified Personality to conduct the Strategic Council for the Healthcare Industry in order to propose a ambitious 10-years plan for innovation in healthcare. [♦ February 2021].
[PRESS RELEASE] – Nomination of CEO
T.H.A.C announces leadership transition appointing Lyse Santoro, Chief Executive Officer and member of the board of directors. [♦ November 2020].
[PARTNERS] – THAC launches a crowdfunding campaign
THAC launches a crowdfunding campaign with the plateform Happy Capital in order to allow healthcare patients and actors to contribute to the THAC story for the benefit of T2DM patients [♦ July 2020]